This article is influenced in many ways by the late Professor John Robertson and his work. First, it deals with new reproductive technologies, a topic to which he devoted so much of his professional life. It is impossible to grapple with issues related to reproductive technologies without considering John\'s important and highly influential views about reproductive autonomy and liberty. His work has been, and will continue to be, present in all discussions about the value and potential limits of new reproductive technologies.

Second, this piece follows from my first piece on in vitro gametogenesis (IVG),^[1](#fn1){ref-type="fn"}^ which I presented at a Baby Markets Roundtable, where John was a commentator on an early draft. At that workshop, he also presented an early draft of a piece exploring another new reproductive technology---uterus transplants---which was ultimately published in this journal.^[2](#fn2){ref-type="fn"}^ John was always intrigued by the ways in which technologies might advance reproductive options and his insights and responses to my first piece on IVG helped improve the piece immeasurably.

Finally, John was a commentator on an early draft of this piece, also presented at a Baby Markets Roundtable, which he co-hosted with Professor Michele Goodwin at the University of Texas Law School. As always, John\'s comments were exceptionally helpful. In addition, he was a gracious host, displaying his characteristic charm, wit, generosity, and sharp intellect. I am so grateful that I was able to attend one of the last professional meetings at which he was present. His passing is such a profound loss to all scholars interested in reproductive rights and emerging reproductive technologies not only because we will miss his voice, wisdom, and insight, but also because we have lost a dear friend and colleague.

INTRODUCTION {#sec2}
============

Important developments in genomic research and reproductive technologies are emerging in ways that could significantly change the reproductive landscape and vastly refine our capacity to select future children. Next-generation sequencing, which allows us to generate ever more meaningful information from biological specimens, will expand the range and nature of information that can be used for reproductive decision making. Improvements in our capacity to understand the clinical and phenotypic significance of genetic variants that correspond not only to diseases, but also to many non-disease traits, will also inevitably influence reproductive choices.

Other technological developments in the future may alter the way we obtain information for reproductive decision making. We are already experiencing some changes with the emergence of non-invasive prenatal testing ('NIPT'), which allows for analysis of fetal cells without the invasive procedures of amniocentesis and chorionic villus sampling.^[3](#fn3){ref-type="fn"}^ While still not a diagnostic test, NIPT is a highly sensitive screening test that has expanded the number of people seeking prenatal information.^[4](#fn4){ref-type="fn"}^

Preimplantation genetic diagnosis ('PGD') offers another mechanism to learn about the future child by conducting genetic analysis of embryos created through in vitro fertilization ('IVF').^[5](#fn5){ref-type="fn"}^ With expanded genomic analysis, PGD could provide a wealth of information for reproductive decision making. Because PGD is expensive and requires the physically burdensome process of egg retrieval necessary for IVF, it is not a widely adopted technique for reproductive decision making.^[6](#fn6){ref-type="fn"}^ However, emerging technologies, such as the creation of gametes in vitro, could change this. When combined with genome sequencing, it could have a profound effect on reproductive testing, leading to efforts to '"perfect" reproduction'^[7](#fn7){ref-type="fn"}^ through a process that has been called 'Easy PGD'.^[8](#fn8){ref-type="fn"}^

Why, one might wonder, would parents choose this method of reproduction over sex? Because it could expand reproductive choice in ways we have never seen. Easy PGD ('EPGD') would allow parents to select embryos for implantation based on disease risks, less significant ailments, and even certain non-medical traits on a scale far beyond what PGD currently allows. While the number of embryos available for PGD today is limited by the number of eggs that can be retrieved from a woman, IVG would make it possible to generate hundreds or thousands of ova. As a result, it would be possible to create just as many embryos, which would maximize parents' ability to identify an embryo with the 'healthiest' or 'optimal' genetic profile.^[9](#fn9){ref-type="fn"}^

The prospect of EPGD raises a host of serious and legitimate concerns. As I have described in earlier work^[10](#fn10){ref-type="fn"}^ and will only briefly revisit here, it could change our reproductive experience, alter our understanding of reproduction, and exacerbate existing inequities. In addition, if EPGD becomes a reality,^[11](#fn11){ref-type="fn"}^ its capacity to offer virtually unlimited reproductive options could lead to enormous decision-making challenges for those who choose this method of reproduction.

Part I describes the technologies that could lead to EPGD, including in vitro gametogenesis ('IVG') and next-generation sequencing ('NGS'). Part II reviews some of the general social and ethical concerns regarding EPGD, while Part III focuses on the decision-making challenges that EPGD would present, which would be unlike any we have seen with current reproductive testing. Next-generation sequencing and increased understanding of the links between genotype and phenotype (the observable characteristics that result from the interaction of genotype with the environment) will provide parents with dizzying amounts of probabilistic information about an enormous range of health risks and traits for each embryo. Making sense of that for one embryo is challenging enough; trying to make sense of it for tens or hundreds of embryos would be even more daunting.^[12](#fn12){ref-type="fn"}^

But the most overwhelming choices parents will confront will be deciding which embryos to implant based on the genomic profiles generated by EPGD. Genomic analysis will reveal heightened risks for some serious diseases and decreased risks for others as well as predictive information about the probabilities of non-medical traits. Trying to decide which genomic profiles possess the combination of propensities for health and non-medical traits that offer the best quality of life for the future child would be challenging if only a handful of embryos were involved. But trying to evaluate the relative tradeoffs among different sets of health risks and traits among tens or hundreds of embryos will be staggeringly difficult. How will parents even begin the process of making such choices, let alone choose? And what will this mean for decision making? While the goal of EPGD would be to maximize parental choice, the vast number of options may in fact lead to paralysing choices and 'choice overload'.^[13](#fn13){ref-type="fn"}^

Although some parents might choose to sort through the enormous amount of information to select embryos for implantation, the sheer quantity of information will undoubtedly lead many to seek some sort of guidance or shortcut to navigate this process. Part IV explores the potential remedies that professional societies, providers, or commercial entities could implement to address some of these decision-making challenges associated with information overload, including limiting the disclosure of certain kinds of information. While such remedies raise issues related to reproductive autonomy, Part V explores an even more vexing remedy: the development of algorithms to assist with the complex task of embryo selection. It argues that this remedy may be worse than the problem it tries to solve by routinizing reproductive decisions based on hidden biases, reducing societal diversity, exacerbating 'choice overload effects', challenging professional norms, and raising the specter of eugenics.

In exploring these issues, the larger goal of this piece is twofold: first, to imagine what reproductive decision making might look like in a world of EPGD and second, to offer some (additional) reasons we should be skeptical about putting resources into the development of EPGD. Rather than expand reproductive choice, EPGD has the potential to create a tyranny of choice.

I.. The Technology Behind Easy PGD {#sec2-1}
----------------------------------

To make sense of the concerns regarding Easy PGD ('EPGD'), it is important to understand the technologies that would make it possible. EPGD would involve the use of four different technologies: *in vitro* gametogenesis ('IVG'), in vitro fertilization ('IVF'), preimplantation genetic diagnosis ('PGD'), and broad-scale genomic analysis, such as next-generation sequencing ('NGS'). Two of these technologies, IVF and PGD, already exist. Genome sequencing is also currently possible, but the technology and our ability to interpret this information leave much room for improvement. Finally, IVG is a promising---but not yet viable---technology for reproduction in humans. The four technologies would be used for EPGD in a multistep process. First, IVG would be used to create a large number of ova. Using IVF, the ova would be fertilized in a petri dish with naturally derived or IVG-generated sperm.^[14](#fn14){ref-type="fn"}^ Finally, using NGS, PGD would identify genetic variants to create a genomic profile for each of the resulting embryos.

Assuming its safety and efficacy, the initial step of IVG would allow us to generate gametes (particularly ova) in vitro as opposed to physically retrieving them from women, which would offer a few advantages. First, it would avoid the physically burdensome and potentially risky process of obtaining eggs, which requires the woman to receive hormone injections so she can produce multiple eggs and to undergo surgery with general anesthesia to retrieve the eggs.^[15](#fn15){ref-type="fn"}^ Second, IVG would allow us to obtain vastly more eggs than we can with current techniques. While hormone treatment can enhance egg production, there are still limits as to how many eggs can be obtained from a woman at any one time.^[16](#fn16){ref-type="fn"}^

In theory, IVG would present no such limits. Increasing the quantity of eggs would make it possible to create many more embryos,^[17](#fn17){ref-type="fn"}^ which could enhance reproductive options. The more embryos available for genomic analysis, the more 'nuanced and comprehensive' the embryo selection process could be.^[18](#fn18){ref-type="fn"}^ As one study noted, to have a 99.99% chance of selecting a particular genotype at 15 loci, one would need to create 10,000 embryos from which to choose.^[19](#fn19){ref-type="fn"}^ Being able to create a large number of embryos would therefore allow for very robust embryo selection.

While IVG is not currently a viable technology for human reproduction, current efforts are underway to make that possible. Given that I and others have provided a more detailed description of the state of the technology elsewhere,^[20](#fn20){ref-type="fn"}^ I offer only a brief account of what IVG involves. At this point, most of the research on IVG has focused on mice, with some impressive results. Researchers have been able to develop viable eggs from somatic skin cells of adult mice, which, when fertilized with naturally derived sperm, have resulted in embryos, and ultimately, the birth of healthy, fertile offspring.^[21](#fn21){ref-type="fn"}^ Numerous other IVF projects are currently underway including those involving primates.^[22](#fn22){ref-type="fn"}^

To date, research on IVG in humans and nonhuman primates has not had the same level of success. Just as with earlier work in mice, the first attempts at IVG in humans involved efforts to derive gametes from embryonic stem cells.^[23](#fn23){ref-type="fn"}^ With advances in stem cell research, scientists have been able to induce and isolate human primordial germ-like cells from human pluripotent stem cells.^[24](#fn24){ref-type="fn"}^ While scientists have yet to produce demonstrably functional human ova, a recent article predicts 'that experimental refinements likely will permit derivation of functional eggs and sperm from human \[induced pluripotent stem cells\] in the not too distant future.'^[25](#fn25){ref-type="fn"}^

Assuming that IVG could lead to the creation of multiple embryos via IVF, the next step would be analysing the embryos with PGD and NGS. How effectively or easily this could be achieved is uncertain and would depend on the state of both technologies. Researchers would first need to overcome several substantial technical challenges so that genome sequencing for EPGD would be accurate, fast, and cheap. This process would require sequencing the 6.4 billion base pairs of the cells removed from the dividing embryo with 'high accuracy' and in a time frame that would both optimize the power of NGS and allow for the successful transfer of an embryo for implantation.^[26](#fn26){ref-type="fn"}^ In addition, the sequencing technology would need to be affordable. Researchers are currently exploring various methods of NGS, although we should expect the nature of large-scale sequencing in the future to be different (potentially much different) from what is possible right now.^[27](#fn27){ref-type="fn"}^ Developing the sequencing technology will be easy, however, in comparison to the challenge of improving our ability to interpret the vast amount of data that NGS could generate. How well we will be able to do that in the future is not clear.

Given that genomic information varies in its significance in determining phenotype, we will need to be able to interpret the genome comprehensively so that we can establish which genetic variants are particularly meaningful and informative. Highly penetrant genetic variants (where the probability is high that the variant will lead to the associated phenotype)^[28](#fn28){ref-type="fn"}^ will be far more informative than low penetrant genetic variants.^[29](#fn29){ref-type="fn"}^ Even with lower penetrant variants, however, NGS may still be able to offer predictions about the likelihood of the phenotype\'s developing.

In theory, large-scale sequencing would ultimately provide comprehensive genomic information about a range of phenotypes---physical health risks, intellectual or cognitive disorders, and non-medical traits. The first two categories could be broken down based on degree of severity and age of onset (eg do they occur in childhood or adulthood?). Non-medical traits would include things like sex, physical characteristics (height, build, hair color, eye color, etc.), temperaments (tendencies toward extroversion, introversion, anxiety, etc.), and capacities in areas such as athletics, scholastics, music, etc. Crucial information would be the probability that the genotype would actually result in the specific phenotype, whether medical or non-medical. A few genotypes would be strongly determinative of phenotype; others would only increase the odds of the phenotypes, sometimes only by insignificant amounts. The degree to which our capacity to interpret the genome improves in the coming years will strongly influence how much we will be able to predict about the health and non-medical traits of future children through EPGD.

As this brief discussion suggests, the ultimate viability and timing of EPGD are to some extent speculative, dependent as they are on the development of many different technologies and the ability to combine them safely, effectively, and affordably. As the late Professor John Robertson observed in commenting on a draft of this piece, EPGD involves a number of technological steps, each of which could be a significant limiting factor: the IVG process, the mechanized fertilization leading to the creation of embryos, and the extensive throughput from NGS and PGD. It would be no small task to make each of these steps safe, effective, and affordable. Difficulties with any one step could slow, or even halt, the emergence of EPGD.^[30](#fn30){ref-type="fn"}^

There are other reasons to be circumspect about whether and how quickly EPGD could become a reality or whether it would become widespread. First, we might be skeptical about how much meaningful information large-scale sequencing will actually provide. But even if it is not fully comprehensive, our capacity to identify and successfully interpret a significant amount of genomic information will surely improve in the coming decades,^[31](#fn31){ref-type="fn"}^ even if much of the information is probabilistic as opposed to fully determinative. Perhaps more uncertain is whether we will be able to create viable eggs and sperm for purposes of reproduction. Epigenetic challenges alone---specifically, altering the imprinting patterns of the genes in the somatic cells that would be used to generate the gametes through IVG to make them consistent with the imprinting patterns of gametes---will be difficult to achieve and will require a great deal of research.^[32](#fn32){ref-type="fn"}^

In addition, even if it becomes technologically possible to generate hundreds or even thousands of embryos, fertility clinics would confront vexing storage and funding challenges. Biobanks currently struggle to find funding to exist in perpetuity.^[33](#fn33){ref-type="fn"}^ And fertility clinics already face storage issues concerning 'abandoned' embryos when gamete progenitors do not pay storage fees or cannot make decisions about disposition of extra embryos.^[34](#fn34){ref-type="fn"}^ One might imagine, therefore, that fertility clinics would institute specific destruction policies for individuals who wanted to create hundreds or thousands of embryos for EPGD.

Another limiting factor might be the fact that some individuals are uncomfortable destroying embryos, even with current IVF. The potential creation and destruction of 'not just a handful of embryos, but literally thousands', would be even more troubling for such people.^[35](#fn35){ref-type="fn"}^ If clinics imposed mandatory destruction requirements, this might further limit the scope of those who use EPGD.

Finally, EPGD would necessarily be limited to planned pregnancies. Given that roughly 45% of pregnancies are unintended,^[36](#fn36){ref-type="fn"}^ many individuals would utilize EPGD technology only with some pregnancies, or not at all. The fact that unintended pregnancy rates are highest among poor and low-income women, young women, cohabiting women, and minority women^[37](#fn37){ref-type="fn"}^ means that those most likely to use EPGD would be higher income, white women, raising serious equity concerns.

In spite of these uncertainties, research is clearly underway to develop and improve technologies that hold real promise and that would be essential to the ultimate feasibility of EPGD. While scientists may not actively try to bring about EPGD, there is good reason to believe it will emerge 'as a "secondary" use, or effect, of many other developments',^[38](#fn38){ref-type="fn"}^ such as advancements in IVG and improvements in DNA sequencing and DNA analysis.^[39](#fn39){ref-type="fn"}^ In addition, even if not everyone would choose EPGD (because of concerns about embryo destruction or because of unintended pregnancies), it is still highly plausible that many people (especially those with the greatest resources and education levels) would take advantage of this technology. As a result, this article operates under the assumption that EPGD could well become a significant, if not widespread, part of our reproductive landscape in the not-too-distant future. With that assumption in mind, I turn, in Part II, to the general issues with respect to EPGD and, in Part III, to the specific decision-making challenges that its emergence could present.

II.. Changing Reproduction in Kind or Degree? {#sec2-2}
---------------------------------------------

In many ways, as I have argued elsewhere, EPGD raises the same kinds of issues as other technological advances in reproduction. Like those technologies, EPGD is not 'per se problematic'; instead much depends on the motivations underlying its use, such as whether they are 'rooted in concern about the best interests of the child and family' or 'based on prejudice or conceptions of the future child only in terms of the presence or absence of disease or traits'.^[40](#fn40){ref-type="fn"}^ Nevertheless, EPGD has the potential to 'subtly shift attitudes about prenatal selection and intensify some of the ... concerns surrounding prenatal selection', such as the exacerbation of inequalities; the reinforcement of prejudice against those with disabilities or undesirable traits; and the commodification of reproduction by viewing children as products to design, rather than gifts to accept.^[41](#fn41){ref-type="fn"}^

Indeed, EPGD's ease and highly refined selection could increase the troubling aspects of reproductive selection to such an extent that it would change the reproductive experience in kind, not just degree. For example, the ability to select among so many embryos based on non-medical traits and less serious diseases could gradually, but profoundly, alter attitudes about what is in the future child\'s best interest. More important, it could shift the goal of selection from preventing harm to 'perfecting' reproduction^[42](#fn42){ref-type="fn"}^ far more than occurs today with prenatal testing. These cultural shifts would routinize selection against not just disabilities, but also disfavored non-medical traits, ultimately leading to a vicious cycle: reproductive choices would reinforce prejudice by reducing the number of children born with the disfavored disabilities or traits, which would increase selection against those traits, thereby further reinforcing prejudice, etc.^[43](#fn43){ref-type="fn"}^ While such a vicious cycle already exists with current reproductive technologies, the degree would be significantly different with EPGD, potentially changing the experience in kind.

In addition, being able to select embryos on the basis of a wide spectrum of medical and non-medical traits enhances the commodification concerns profoundly. Parents might fixate on the full spectrum of medical and non-medical traits they tried to avoid or cultivate through EPGD, leading to parents to see their children in terms of their potential traits. Heightened expectations might substantially raise the possibility for disappointment if children don't measure up to those expectations.

EPGD also magnifies concerns about depriving the child of an open future because it would allow parents to learn about diseases that may develop later in life. Such a result would challenge the long-held view that children should generally not be tested for late-onset conditions, but should instead be allowed to decide as adults whether they want to learn such information.^[44](#fn44){ref-type="fn"}^

Finally, EPGD could 'impoverish the informed consent process as providers and patients view \[embryo selection\] as routine, rather than a deeply personal choice that is not necessarily for everyone'.^[45](#fn45){ref-type="fn"}^ To be sure, informed consent is already routinized to some extent with prenatal testing,^[46](#fn46){ref-type="fn"}^ but this will occur to a much greater degree with EPGD, particularly if the various pressures discussed in Part III motivate enough people to use it for its refined means of selection. In addition, as Part III argues, EPGD will raise additional challenges to informed consent, leading to paralysing choices and choice overload. Unfortunately, the potential remedies to these informed-consent challenges, as Part V argues, have the potential to further routinize the decision-making process in ways we have not seen, potentially changing the experience of reproduction. Before addressing that issue, however, we turn to the paralysing choices of EPGD.

III.. Paralysing Choices and Choice Overload {#sec2-3}
--------------------------------------------

The rationale for combining IVG, IVF, PGD, and NGS to develop EPGD would be to offer parents a range of reproductive choices: specifically, to be able to select against certain medical conditions and/or to select for or against certain non-disease traits.^[47](#fn47){ref-type="fn"}^ In spite of that goal, there are reasons to think that this expansion of choice could potentially be overwhelming for many. As Section III.A suggests, just trying to process and make sense of the vast amount and different kinds of information that EPGD could generate to decide what information would be valuable for selecting embryos could be overwhelming. On top of that, as Section III.B describes, would be the challenge of deciding what information would be valuable for selecting embryos. Finally, Section III.C explores the most difficult decision of all: evaluating the relative tradeoffs of the genomic profiles of so many embryos and choosing which embryo(s) to implant.

### A.. Information Overload and Comprehension Challenges {#sec2-3-1}

To take advantage of EPGD, future parents would first have to understand the range and type of information that EPGD could generate. This could prove complex and logistically difficult because it would provide information about hundreds or thousands of variants. The sheer quantity of information will present informational challenges. In addition, the phenotypic implications of genetic variants associated with medical conditions can differ widely in terms of the nature of the condition, the age of onset, severity, whether treatment or prophylactic measures are available, expressivity (how variable the phenotypic expression of the disease is^[48](#fn48){ref-type="fn"}^), and penetrance (the probability that the variant will lead to the associated condition^[49](#fn49){ref-type="fn"}^). Further complicating matters, the significance of some variants will be unknown.^[50](#fn50){ref-type="fn"}^

To decide what kind of information to obtain, one would need to understand the nature of information available through EPGD as well as its implications. Educating patients about all of the potential genetic variants that could be identified and their different phenotypic implications would take an enormous amount of time and personnel. Some have estimated that it would take two to six hours of in-person genetic counseling over several sessions.^[51](#fn51){ref-type="fn"}^ That estimate does not include discussions about non-medical trait information. Even with an adequate number of genetic counselors and sufficient time, most individuals would have difficulty absorbing so much complex, largely probabilistic, and varied information. EPGD could, therefore, present significant problems of information overload and comprehension challenges even before people faced their first decision: determining what kind of information would be relevant for their reproductive choices with EPGD.^[52](#fn52){ref-type="fn"}^

### B.. Paralysing Choices and Choice Overload {#sec2-3-2}

Even if we could establish mechanisms to ensure adequate comprehension of the vast and varied amount of information genomic analysis could provide with EPGD, people would still face numerous challenges in deciding what information to obtain and what to do with it.

#### 1.. Deciding What to Learn {#sec2-3-2-1}

Deciding what kind of genomic information one wants to receive is not unique to the reproductive context. For example, while most individuals would want information about medically actionable health risks in the adult genetic testing context,^[53](#fn53){ref-type="fn"}^ they may be uncertain about the value of learning information related to health risks for which there are limited or no interventions. People are often not good predictors, *ex ante*, about the kind of information they will want when they actually confront the option to obtain such information.^[54](#fn54){ref-type="fn"}^ It is, after all, sometimes very hard to know what our future desires will be.

These challenges are potentially even greater in the reproductive context where the interest in and desire for genetic information is not simply a medical decision, but a choice based on personal values and circumstances. Certainly such factors come into play with many medical decisions to varying degrees. But personal values and circumstances are particularly central to decisions concerning prenatal testing---by which I mean amniocentesis, chorionic villus sampling, or NIPT, as opposed to (ordinary or Easy) PGD^[55](#fn55){ref-type="fn"}^---because, currently, prenatal testing is not offered with the goal of providing treatment for serious medical conditions.^[56](#fn56){ref-type="fn"}^ Instead, its goal is to give parents the opportunity to prepare for the birth of a child with an identified medical condition or to consider pregnancy termination or placing the child for adoption. Because there is usually no medically 'optimal' choice, decision making in this context is especially influenced by one\'s beliefs and personal situation. It is a complicated process inextricably intertwined with issues of reproductive autonomy^[57](#fn57){ref-type="fn"}^ and also linked to desires for reassurance and efforts to do what is best as a parent.^[58](#fn58){ref-type="fn"}^

Prenatal information can be a double-edged sword, both relevant to reproductive decisions and potentially anxiety provoking.^[59](#fn59){ref-type="fn"}^ It may be difficult for individuals to know, in advance, what the information would mean to them, how it might affect their reproductive decisions and planning, or whether it would contribute to anxiety in the pregnancy. As a result, decision making is complex even in the current environment where prenatal testing focuses on a single or limited number of conditions. If NGS becomes part of prenatal testing, deciding what information would be relevant for reproductive choice will become even more complicated.

Some of the same considerations would influence decisions about what information to obtain when using NGS in the context of ordinary or Easy PGD.^[60](#fn60){ref-type="fn"}^ But the relevance of genomic information will often differ depending on whether it is obtained through prenatal testing or PGD. Rather than influencing decisions about termination or adoption, as it would with prenatal testing, genomic information from (E)PGD would influence the selection of embryos for implantation.^[61](#fn61){ref-type="fn"}^ Because PGD does not involve considerations of whether to continue a presumably wanted pregnancy, parents would probably find a broader swath of genomic information relevant to (E)PGD as compared to prenatal testing. In other words, information that might not influence decisions about whether to continue a pregnancy, such as lesser medical risks, could potentially influence decisions about which embryos to implant.

As researchers discover more meaningful associations between genetic variants and non-medical traits, comprehensive genomic analysis will force us to consider the relevance of information about non-medical traits in this context. Certain non-medical traits, such as sex, influence decisions to terminate pregnancies in some countries.^[62](#fn62){ref-type="fn"}^ In the United States, however, few find this information relevant for pregnancy termination, although parents often want to learn the sex of the fetus for planning purposes or merely to satisfy curiosity.^[63](#fn63){ref-type="fn"}^ One would therefore expect non-medical trait information generally to be less relevant to decisions about whether to continue a pregnancy than information about serious medical risks.^[64](#fn64){ref-type="fn"}^

Indeed, as more non-medical trait information becomes available through prenatal testing, parents might be even less likely to terminate based on this information because it would include a mixed bag of more and less 'desirable' traits. For example, genomic analysis could reveal an increased propensity for certain characteristics the parents might not prefer (eg shorter stature^[65](#fn65){ref-type="fn"}^) in combination with an increased propensity for traits the parents particularly value (eg musicality^[66](#fn66){ref-type="fn"}^). The more comprehensive and complex the genomic profile of the fetus, the better the odds it would only satisfy curiosity and not assist with decisions about whether to continue a pregnancy.

In the context of ordinary or Easy PGD, however, genomic information about non-medical traits would probably be far more material for embryo selection. The question would not be 'Should I continue this pregnancy with a child that has some traits I wish were different?' Instead, the question would be, 'Should I implant an embryo with this particular combination of traits instead of the other embryos with different combinations of traits?' Even here, not all non-medical trait information would be important for embryo selection. And even if it were important, most parents would probably not consider such information as consequential as information about health risks. Nevertheless, many parents would probably want to consider whether and to what extent trait information would help them select embryos.^[67](#fn67){ref-type="fn"}^

Those choosing to procreate via EPGD, therefore, would probably find a wide range of information (regarding both medical risks and non-disease traits) relevant to embryo selection. After all, the point of pursuing this mode of reproduction would be to maximize the chance of finding an embryo with the 'best' possible genomic profile (however 'best' would be understood). Because not all of the potential information would be equally important to this decision and because the disclosure of too much information could complicate the process of selecting embryos, parents would probably prefer to receive only the information they would find useful for embryo selection. This would require deciding in advance what information would be valuable, a very challenging process indeed.

#### 2.. Choosing Embryos---A Paralysing Choice? {#sec2-3-2-2}

Deciding what information to obtain for reproductive decisions is quite different from actually deciding what to do once one has the information. Before exploring these challenges with respect to EPGD, I begin with the prenatal testing context.^[68](#fn68){ref-type="fn"}^ The difference between decisions in these two contexts helps highlight how paralysingly difficult decisions in the latter context might be.

As noted earlier, prenatal testing differs from (E)PGD in that the decision is limited to questions about a single pregnancy.^[69](#fn69){ref-type="fn"}^ With targeted genetic testing, parents often consider in advance whether information about a clinically relevant variant would be useful to prepare for the birth of a child with the condition or to decide whether to continue the pregnancy or place the child for adoption. Even if many cannot know for sure how they will respond before getting results, most give serious thought to the options. With genomic analysis, however, parents cannot possibly fully contemplate their potential responses to the enormously broad range of information they could receive.

In addition, genomic analysis could reveal information about risks for conditions that vary in likelihood and severity. Parents could learn, for instance, that the fetus faced a higher than average risk of a few adult-onset conditions, such as pancreatic cancer, type 1 diabetes, and coronary heart disease; a higher than average risk of bipolar disorder; a lower than average risk of autism and asthma; a higher than average chance of exceptional athletic abilities; and a lower than average chance of musical ability. Reproductive decisions based on this complicated and unpredictable constellation of risks would be much more complex than decisions based on a high risk of a medical condition, which the parents would have thought about at some length.

When we consider genomic analysis in the context of (E)PGD, the decision making would be even more complex. Not only would more genomic information be relevant to decisions about embryo selection,^[70](#fn70){ref-type="fn"}^ but individuals would have to consider the genomic profiles of not just one embryo, but multiple embryos with ordinary PGD, or tens, hundreds, or possibly even thousands^[71](#fn71){ref-type="fn"}^ of embryos with EPGD, an enormous task in itself.

Even more difficult would be comparing the relative tradeoffs of the various genomic profiles to decide which embryos to implant because each genomic profile would present a different set of risks. Trying to assess the relative costs and benefits of the different variants identified in each of the embryos would be further complicated by the fact that the disease risks could vary in several respects: probability of manifestation, degree and range of severity, age of onset, treatment options, etc. How would one choose, for example, between an embryo with a genomic profile indicating an increased risk of coronary artery disease, colon cancer, and type 1 diabetes and a decreased risk of schizophrenia, breast and ovarian cancer, and asthma, and another embryo with an increased risk of bipolar disorder, cataracts, autism, and breast cancer and a decreased risk of leukemia, Parkinson\'s disease, and lung cancer.^[72](#fn72){ref-type="fn"}^ Now imagine trying to make such comparisons for not just two or ten embryos (with ordinary PGD), but for tens, hundreds, or thousands of embryos, as one might with EPGD. The vastly increased magnitude of options would materially change the experience, making it exceptionally difficult, if not virtually impossible or paralysing.

Including trait information in the analysis would further complicate the decision. Even if one focused on disease risks and used trait information as a tie breaker for embryos with similar disease risks (however determined), difficult tradeoffs would be inevitable. Several embryos might have numerous traits that are both desirable and undesirable to the parents. Imagine, for example, the genomic analysis of one embryo: female, who would experience early graying and be moderately tall with a heavy build; 65% chance of scoring in the top half of the SAT tests; good chance of above-average athletic ability; and likely to be introverted. Now imagine the genomic profile of another embryo: male, who would have male-pattern baldness, medium height, and medium build; 40% chance of scoring in the top half of the SAT tests; likely to have above-average musical ability; and likely to be anxious.^[73](#fn73){ref-type="fn"}^ How would one compare the complex mix of non-medical traits of just two embryos, let alone tens or hundreds of embryos?

The problem, quite simply, is one of 'choice overload'.^[74](#fn74){ref-type="fn"}^ Studies in various contexts have shown that a proliferation of choice can lead to decision-making difficulties.^[75](#fn75){ref-type="fn"}^ What\'s worse, not only can choice overload affect decision making, it has also been shown to lead to reduced satisfaction with the choice that one ultimately makes.^[76](#fn76){ref-type="fn"}^ If similar dissatisfaction arose with EPGD, this could intensify the concerns about commodification of children and the threat of disappointment if heightened expectations were dashed.^[77](#fn77){ref-type="fn"}^

As we have seen, EPGD will present a number of decision-making challenges: comprehending the enormous range of information it could provide; deciding what information to obtain; and finally, using the information to select among tens, hundreds, or possibly thousands of embryos. While, in theory, the potentially endless array of options would maximize choice, EPGD could, in practice, present paralysing choices for many.

### C.. The Pressures in Favor of EPGD {#sec2-3-3}

Before turning to the approaches that might be used to remedy these decision-making challenges, I want to take a moment to respond to the objection that, even if EPGD were to become technologically feasible, the demand for it would be rather low because of the concerns described above. I am skeptical about that prediction given the many countervailing pressures in favor of EPGD, such as a thirst for information, strong marketing efforts, incentives created by insurance companies and wellness programs, competitive pressures among future parents, and clinics' attempts to avoid liability. For example, history suggests that the drive for information will be too great for parents and commercial ventures to ignore. As Barry Schwartz argues in *The Paradox of Choice: Why More is Less*, technology and cultural norms have led to a 'vastly expanding ... range of choices' in virtually all areas of our life, including what items to buy, what health insurance and retirement plans to purchase, what medical care to accept, how to work, how to pray, how to love, and even who to be.^[78](#fn78){ref-type="fn"}^ Yet, even though this proliferation of 'choice no longer liberates, ... \[and\] might even be said to tyrannize', societal pressures push toward more, not less, choice. Our society is 'enamored of freedom, self-determination, and variety, and we are reluctant to give up any of our options'.^[79](#fn79){ref-type="fn"}^ In addition, a deep cultural belief that knowledge provides power and control would feed a desire for as much reproductive information as possible, helping to fuel consumer demand and bring EPGD to fruition.

Marketing efforts are also likely to strengthen these cultural norms. One can imagine advertising that would promote the value of maximizing reproductive options through EPGD. We have already witnessed such efforts with respect to NIPT, which is touted as providing information that offers control and reassurance.^[80](#fn80){ref-type="fn"}^ EPGD marketing could similarly prey on notions of responsible parenthood,^[81](#fn81){ref-type="fn"}^ urging people to use EPGD to ensure their future children are as healthy, talented, and successful as possible.

Insurers might also influence consumer demand.^[82](#fn82){ref-type="fn"}^ Today most insurers do not cover PGD,^[83](#fn83){ref-type="fn"}^ which is more expensive than a natural pregnancy with prenatal testing and an abortion. When assessing cost-effectiveness, insurers do not tend to consider a reproductive test\'s ability to reduce the lifetime costs of caring for children with serious illnesses because people do not tend to stay with a particular insurer for a long time.^[84](#fn84){ref-type="fn"}^ Thus, even if (E)PGD could prevent the birth of (and associated costs of caring for) a child with a significant health risk, insurers would likely only cover EPGD if its cost was sufficiently low and the information it generated could avoid the need for prenatal testing and pregnancy termination to avoid many diseases. Also relevant to insurance coverage of EPGD would be the recommendations of professional organizations. To determine whether reproductive tests are medically necessary for coverage decisions, 'virtually all' insurance plans rely on the American College of Obstetricians and Gynecologists' assessments of the value of the test.^[85](#fn85){ref-type="fn"}^ Over time, we have seen a shift in cost justifications and professional acceptance of a wider scope of NIPT for a broader range of consumers. One could imagine a similar evolution with EPGD.

Employee wellness programs, which aim to reduce health care costs by encouraging employees to engage in healthy behavior, might also create incentives to use EPGD.^[86](#fn86){ref-type="fn"}^ Most such programs focus on carrots or sticks to influence behavior that affects *employee* health. But one could envision some employers offering discounted insurance premiums or co-pays for employees who used EPGD to reduce the health care costs of their *dependents.* While there is no evidence that wellness programs include PGD today, this might change if the cost of EPGD were substantially cheaper than the current cost of PGD. Creating incentives for employees to use EPGD as part of wellness programs could certainly increase the demand for this technology.^[87](#fn87){ref-type="fn"}^

In addition, given competitive pressures to achieve high success rates, fertility clinics might encourage fertility patients to use EPGD. By producing so many embryos, EPGD could substantially increase the odds of producing viable embryos. In addition, genetic analysis might become valuable in assessing embryo viability.^[88](#fn88){ref-type="fn"}^ While full genome analysis might not be necessary for that purpose, once the costs and throughput of the technology became manageable, clinics might offer large-scale sequencing as an add-on feature for fertility patients.

The biggest motivator for clinics to encourage patients to use EPGD, however, would be to reduce the threat of liability. Clinics might worry that fertility patients who don't use EPGD would sue for wrongful birth claims ^[89](#fn89){ref-type="fn"}^ if the resulting child had a condition that could have been detected through genome sequencing of the embryo that was implanted and which could have been prevented had another embryo without the relevant genetic mutations been implanted.^[90](#fn90){ref-type="fn"}^

Currently, wrongful birth claims arise when specific risk factors---eg when both parents are carriers of a gene for a recessive condition---warrant targeted genetic or other diagnostic testing. With large-scale sequencing, however, many genetic mutations associated with disease could be identified without a prior known risk. If EPGD becomes viable, fertility clinics might try to protect themselves against wrongful birth liability by asking patients who don't undergo EPGD to sign waivers or exculpatory clauses agreeing not to sue the clinic for wrongful birth. Whether courts would uphold such claims would depend on their views as to the importance or necessity of the service and the relative bargaining power of the patient and the clinic.^[91](#fn91){ref-type="fn"}^ If enforceable, these provisions would create yet another incentive for fertility patients to choose EPGD.

Finally, if individuals with fertility issues began to use EPGD in increasing numbers, it might not be long before EPGD moved out of the realm of infertility treatment to become mainstream. Those who could reproduce the 'old-fashioned' way might not want to lose out on the competitive advantages EPGD could potentially provide. We already witness significant parental efforts, in certain segments of society, to maximize children\'s competitive advantages through private coaching, music lessons, tutoring, college preparatory programs, enrollment in elite schools (from preschool to college), etc. Selecting embryos with the greatest probability of possessing physically and culturally advantageous traits through EPGD would be just one more way to increase the competitive advantages for one\'s future child.

For all of these reasons, it seems highly plausible that, in spite of the concerns regarding EPGD, the demand and market for this technology would not be insignificant. Providers of EPGD would therefore have strong incentives to address its decision-making challenges so they could more fully promote the technology. I turn now to the remedies that these different entities might develop to achieve that goal, beginning with those that address comprehension issues and decisions about what information to obtain in Part IV. Part V then turns to the most vexing remedy for the decision-making challenges of EPGD---the creation of algorithms to help parents select embryos.

IV.. Remedies to Address Paralysing Choices {#sec2-4}
-------------------------------------------

Two types of providers of EPGD would have incentives to minimize the decision-making challenges of EPGD. Professionals involved in the delivery of this technology might feel professionally and morally obligated to address these problems so that patients are not overwhelmed (assuming their guidelines condoned the use of EPGD). Commercial providers would also be quite eager to prevent these difficulties so they could better market the technology as offering a sense of empowerment.^[92](#fn92){ref-type="fn"}^ I should note at the outset that my efforts to distinguish between these two groups may be more conceptual than actual. In theory, they represent two different kinds of actors, but the line between the two is becoming increasingly blurry. Section IV.A discusses potential efforts to maximize comprehension. Section IV.B explores potential efforts to help patients decide what information to obtain, suggesting that some of the remedies may challenge reproductive autonomy and raise equity concerns.

### A.. Understanding the Range of Possible Information {#sec2-4-1}

I only briefly address remedies for the comprehension issues related to EPGD because these are the least problematic. Given the impossibility of outlining the significance of all of the genetic variants that could be identified from genome sequencing, as well as the difficulties people might experience trying to comprehend such information,^[93](#fn93){ref-type="fn"}^ scholars have recommended categorizing genomic information based on various features. In the context of NGS in the population at large, one suggestion has been to divide the information into 'bins' based on characteristics associated with medical conditions, such as age of onset, medical actionability, severity, and likelihood of the condition\'s developing.^[94](#fn94){ref-type="fn"}^ With respect to genome sequencing in prenatal testing, one group recommended presenting information to parents on the basis of three dimensions: (1) the type of information that genomic analysis could provide---'physical; intellectual and cognitive; psychiatric; life-shortening/lethal conditions; and nonmedical', (2) the clinical severity of the conditions, and (3) the 'probabilistic level of association between genotype and phenotype'.^[95](#fn95){ref-type="fn"}^ Such an approach could become a practical necessity for prenatal testing if it ultimately includes NGS, especially if parents have discretion to determine the scope of information they receive. Similar approaches would likely be used for EPGD.

Because the information would be expressed in probabilistic terms, however, the comprehension challenges would be still be daunting for many, especially considering how pervasive innumeracy is.^[96](#fn96){ref-type="fn"}^ Nevertheless, while the bin approach has its limitations,^[97](#fn97){ref-type="fn"}^ we simply do not have sufficient resources or time (from both practitioners' and patients' perspectives) for providers to offer a detailed account of all of the information generated by this kind of testing.^[98](#fn98){ref-type="fn"}^ Decision aids, however, could be used to supplement the bin approach. They might provide general descriptions of the categories, giving individuals the option to explore more detailed descriptions with respect to each category in more depth and on their own time.^[99](#fn99){ref-type="fn"}^ These solutions would not be perfect, but they might be the best we can do under the circumstances.

### B.. Deciding What Information to Obtain {#sec2-4-2}

Comprehending the vast amount of information that EPGD could provide is just the first step in the decision-making process. Deciding what information might be relevant in selecting embryos would be even more difficult. As we shall see, various actors might develop and/or offer strategies to combat these difficulties.

#### 1.. Professional Guidelines {#sec2-4-2-1}

Professional groups might try to ameliorate this problem by limiting how much genomic information is disclosed. In spite of the long-standing deference toward patient autonomy in genetics,^[100](#fn100){ref-type="fn"}^ professionals have begun to consider some limits on patient choice. For example, the American College of Medical Genetics and Genomics Working Group initially recommended informing patients undergoing whole genome sequencing about genetic variants associated with certain inherited, monogenic conditions 'amenable to medical intervention', whether or not patients had consented to such disclosure. The justifications for departing from an autonomy-based model of disclosure were principles of beneficence and the obligation to avoid harm as well as concern about limited resources and capabilities of laboratories and medical professionals.^[101](#fn101){ref-type="fn"}^ While updated recommendations allow patients to opt out of such disclosure, they do not call for personal tailoring of genome sequence results.^[102](#fn102){ref-type="fn"}^

Similar concerns about beneficence and limited resources have led to recommendations to *limit* disclosure of genomic information with uncertain or no clinical significance.^[103](#fn103){ref-type="fn"}^ Such information could overwhelm patients by expanding the amount of information they receive and could cause confusion about its significance (or lack thereof). If misunderstood, it could lead to anxiety and/or inappropriate clinical action.^[104](#fn104){ref-type="fn"}^

As we consider introducing genome sequencing in prenatal testing, professional organizations and scholars are debating whether medical professionals should play a gatekeeping role with respect to information disclosure. In part, to remedy decision-making challenges of broad-scale testing, some scholars advocate professional self-regulation, whereby professional societies would offer 'high-value information ... as a default part of the standard of care'.^[105](#fn105){ref-type="fn"}^ How the lines would be drawn is not fully clear, but they could, for example, distinguish between serious medical conditions and minor medical conditions or non-medical traits. Others argue that, to protect reproductive autonomy, parents should be the ultimate arbiters.^[106](#fn106){ref-type="fn"}^ Even these scholars, however, recognize the complexity of such decisions and therefore propose a default option whereby providers could decide the scope of information disclosure for patients who find such choices taxing.^[107](#fn107){ref-type="fn"}^

Similar debates have played out with respect to PGD as scholars and advisory committees consider whether parents should be able to receive non-medical trait information in addition to information about disease risks.^[108](#fn108){ref-type="fn"}^ These debates have focused primarily on the societal and ethical concerns of selecting embryos based on traits, such as sex, rather than concerns about information overload. But if large-scale sequencing is used with PGD (whether ordinary or Easy), professionals might want to limit the scope of disclosure to minimize these problems.

At the heart of these debates are questions of the clinical utility of genomic information in the reproductive context. There are no clear guidelines for assessing clinical utility,^[109](#fn109){ref-type="fn"}^ which can be defined narrowly---in terms of only preventing or ameliorating health outcomes^[110](#fn110){ref-type="fn"}^---or broadly---in terms of the 'medical and social outcomes of testing' and potential interventions,^[111](#fn111){ref-type="fn"}^ such as preparing for the care of an affected child or helping make decisions about termination or adoption. Genetic variants largely predictive of serious diseases clearly have clinical utility under either definition. Whether highly penetrant variants associated with non-medical traits also have clinical utility in the reproductive context is more complicated. Under the broader definition, some non-medical traits might have clinical utility because of their potential social impact on parents. Such information has not, however, been treated as having clinical utility thus far.^[112](#fn112){ref-type="fn"}^

One might argue that a wider range of genomic information is material for PGD as compared with prenatal testing decisions,^[113](#fn113){ref-type="fn"}^ and therefore the broad definition of clinical utility would include non-medical information. Concerns about information overload, comprehension challenges, and limited resources (too few counselors and insufficient time), however, could lead professional societies to limit the scope of clinical utility. By limiting disclosure to information with clinical utility under the narrow definition, providers could better educate patients about, and patients could better comprehend, the limited information they receive. In addition, professional organizations might want to limit the use of medical resources for what could be viewed as 'trivial' reasons to select embryos.

Professional guidelines that limited the scope of genetic information disclosed through (E)PGD would, however, raise concerns about reproductive autonomy and medical paternalism given that the import of reproductive information has long been defined in terms of the patient\'s personal values, preferences, and circumstances. While professional considerations about the use of limited and scarce resources argue against unlimited patient autonomy, the possibility of obtaining broad amounts of non-medical information will force the medical profession and society to think hard about the appropriate scope of patient autonomy in this context. In short, this remedy pits professional autonomy and integrity against patient autonomy.^[114](#fn114){ref-type="fn"}^

#### 2.. Commercial Entities {#sec2-4-2-2}

If professional guidelines limited disclosure only to genomic variants associated with serious conditions, some fertility clinics might fill the void by offering to provide information about variants associated with lesser health risks or non-medical traits. Although commercial labs would do the sequencing, the clinics might request more expansive analysis when sending samples to the labs. Commercial labs might also market their ability to provide more comprehensive genomic analysis, which could lead patients to demand more information from EPGD than the guidelines allow. One could imagine advocates of patient autonomy urging clinics to offer more expansive disclosure, much as they have pushed for broader access to genetic information through direct-to-consumer testing.^[115](#fn115){ref-type="fn"}^ While some providers would adhere to professional guidelines, a good many might flout them for a competitive edge. Indeed, in the unregulated ART world, evidence suggests providers or clinics often ignore professional recommendations. For example, surveys of obstetricians and gynecologists show that 'a high proportion' offer expanded carrier screening 'upon patient request', in spite of the fact the American College of Obstetricians and Gynecologists and the American College of Medical Genetics and Genomics recommend more limited screening panels.^[116](#fn116){ref-type="fn"}^

On the other hand, fertility clinics would have incentives to prevent consumers from feeling overwhelmed by the sheer volume of information EPGD could generate. To allow for personal tailoring of information disclosure, they might offer different packages---eg a 'full-disclosure' package for consumers who want to know everything; a 'health' package, with disclosure of information limited to significant health risks; or a personalized disclosure package based on selected categories of information: health risks (segregated by age of onset, neurological, physical, etc.) and trait information (divided by appearance, intellectual abilities, temperament, aptitudes, etc.).^[117](#fn117){ref-type="fn"}^ If the expense of licensing multiple packages is prohibitively expensive for some clinics, they might offer only one algorithm and differentiate themselves based on the kind of information their algorithm provided.

#### 3.. Insurers and Inequities {#sec2-4-2-3}

Finally, depending on their coverage decisions, insurers could potentially influence the scope of information disclosure and, ultimately, equality. If insurers covered EPGD, they would look to professional organizations' assessments of clinical utility to decide the scope of coverage. If such groups concluded that genomic information about non-medical traits or minor medical conditions had no clinical utility,^[118](#fn118){ref-type="fn"}^ insurers would not cover disclosure of these variants. In practice, this would mean that labs would generate the genomic sequence, but insurance would only cover analysis of variants associated with highly penetrant *medical* conditions.^[119](#fn119){ref-type="fn"}^ Such limitations on insurance coverage would not, however, prevent labs from offering broader analysis if there was sufficient market demand.^[120](#fn120){ref-type="fn"}^

The inevitable result would be two tiers of EPGD consumers: those whose analysis was limited to results for which there was insurance coverage and those with the means to obtain a broader range of genomic information, including information about non-medical traits. Being able to select on the basis of some non-medical information might merely fulfill parental preferences (eg green eyes over blue). But some selection might be for traits associated with societal advantages---such as height, intellectual ability, or impulse control. If access to this broader information was influenced by wealth, those with societal advantages (higher income, better education, access to health care, etc.) would be able to further enhance the opportunities for their future children by selecting for advantageous genetic variants.

If insurers did not cover EPGD, the scope of disclosure by commercial entities would be limited to information for which a sufficient portion of the market was willing to pay to make it cost effective, which would probably be broader than professional guidelines. In addition, only the wealthiest would be able to take advantage of this technology. The social inequities would be even starker here. Not only would the wealthier be able to select for advantageous traits, they would also be better able to use EPGD to avoid the burdens of caring for a child with serious illnesses, even though they would have the financial wherewithal to bear such burdens compared to those who could not afford EPGD.

As we have seen, attempts to ease the challenges of deciding what information to obtain through EPGD would not only test the limits of reproductive autonomy, especially for the most disadvantaged, but they could also heighten social inequities in a world of unequal access to health care and limited social support systems. These are not, however, the most troubling remedies for the decision-making challenges of EPGD, as Part V describes.

V.. Algorithms---Is the Remedy Worse Than the Disease? {#sec2-5}
------------------------------------------------------

We turn now to the most vexing potential remedy for the paralysing choices of EPGD: algorithms. Section V.A. describes the two kinds of algorithms---individualized or generic---that could be used to help individuals with the difficult task of selecting among large quantities of embryos that present complicated tradeoffs of medical risks and traits. Section V.B describes the general issues algorithms present for reproductive decision making and the specific issues they raise, depending on who creates them.

### A.. Algorithms as a Remedy for Paralysing Choices {#sec2-5-1}

Professional groups, fertility clinics, and/or commercial labs might develop individualized or generic algorithms to help individuals process and sort through the results of EPGD.^[121](#fn121){ref-type="fn"}^ Individualized algorithms would use parents' responses to questionnaires about their preferences to evaluate the embryos' genomic profiles and determine which embryo(s) had the highest overall score. Parents might identify the disease and/or non-disease traits they wanted to select against or for and the relative weights they would assign these categories, or they could just rank features most important to them and let the algorithm assign relative weights.

Even this task, however, could prove highly taxing. Some might find it too difficult or abstract to assign rankings or relative weights to different kinds of genomic information. As a result, providers of EPGD might develop generic algorithms. For example, they could create algorithms that award points for genotypes associated with diseases based on various categories: the potential severity, age of onset, degree of impairment or physical suffering, etc. Different weights would be assigned to different categories and the scores would be discounted by the probabilistic association between the variants and phenotype (penetrance).^[122](#fn122){ref-type="fn"}^ These algorithms would be much like assessing quality-adjusted life years ('QALY')---if the goal were to select for embryos^[123](#fn123){ref-type="fn"}^---or disability-adjusted life years ('DALY')^[124](#fn124){ref-type="fn"}^---if the goal were to select against embryos. The resulting scores, based on the genomic profile of each embryo, would be used to select embryos for implantation. The outcome of these algorithms would depend as much on the weights assigned to the categories as to the determination of which categories to use. Two algorithms that used the same categories could lead to very different outcomes if different weights were assigned to each category. In other words, the formulas could have significant impact on the selection of embryos.

Individualized features could be used to modify generic algorithms based on key parental dislikes or predilections regarding medical and non-medical traits. Parents might indicate that a specific category of disease risk, such as a propensity for conditions that require specialized diets, like Celiac disease, would be a deal breaker. All embryos with an increased propensity for such diseases would be excluded,^[125](#fn125){ref-type="fn"}^ and the genomes of the remaining embryos would be ranked based on the generic algorithm. Conversely, only embryos with a significantly increased propensity for a particular trait, such as variants associated with intelligence (assuming a meaningful correlation between variant and trait)^[126](#fn126){ref-type="fn"}^ would be selected for ranking according to the generic algorithm.^[127](#fn127){ref-type="fn"}^

Algorithms might also vary as to whether they factor in information about genetic variants associated with non-medical traits (which might depend on professional guidelines and who developed the algorithm). Individualized algorithms could offer parents the opportunity to decide what kinds of non-medical traits they wanted to include and the weight they would assign those traits. Alternatively, clinics might offer generic algorithms that include certain non-medical traits, perhaps relying on surveys of community preferences or based on the degree to which they were associated with 'success' or other measures of well-being, however defined or understood. As with variants associated with disease, values assigned to traits would have to be discounted based on the probabilities of expression.^[128](#fn128){ref-type="fn"}^

In designing algorithms, ART providers and clinics would have to decide to what extent they would allow patients to determine which traits to select for or against. For example, it is unlikely that providers would let future parents decide whether or not to select embryos based on lethal or debilitating childhood illnesses like Tay Sachs or Lesch Nyhan. Most clinics would likely use algorithms with a baseline selection against such devastating conditions. A more complicated issue is whether providers would be willing to honor other kinds of requests, particularly those that involve the selection *for* less serious disabilities. There are anecdotal cases of providers who have denied patients' requests to implant embryos identified through PGD as having genes associated with deafness or dwarfism. Some clinics, however, will implant such embryos,^[129](#fn129){ref-type="fn"}^ suggesting there may be great variation as to how much algorithms would be personalized.^[130](#fn130){ref-type="fn"}^

Judith Daar has written thoughtfully about the challenges to physician autonomy that arise when patients want to use PGD to select for genetic anomalies. As she points out, 'providers are not obligated to meet every patient demand for treatment.'^[131](#fn131){ref-type="fn"}^ She suggests that support for physician autonomy in this context may arise not only with respect to concerns about 'the medical appropriateness of the treatment', but also 'from a place deep within the doctor\'s personal identity'.^[132](#fn132){ref-type="fn"}^ The Ethics Committee of the American Society for Reproductive Medicine recently grappled with these dilemmas in an opinion on the legitimacy of transferring genetically anomalous embryos. It found that 'valid and reasoned arguments exist to support provider decisions to assist in transferring genetically anomalous embryos, and in declining to assist such transfers'. In cases 'in which a child is highly likely to be born with a life-threatening condition that causes severe and early debility with no possibility of reasonable function',^[133](#fn133){ref-type="fn"}^ however, the Committee found that '\[p\]hysician assistance in the transfer of \[such\] embryos is ethically problematic and highly discouraged.'^[134](#fn134){ref-type="fn"}^ Should EPGD clinics follow these guidelines, one would expect great variety in the kinds of algorithms that clinics would use based on their willingness or reluctance to allow for selection based on certain genetic anomalies and possibly even some non-medical traits.

For all of these reasons, if EPGD were to become a reality, one could imagine fertility clinics offering a range of algorithms. Some might offer highly individualized algorithms for those who wanted full choice; others might offer more limited individualized algorithms. Still others might offer some kind of generic algorithm for those who wanted more assistance: generic algorithms that focus on health features, such as a reduced risk of serious childhood illnesses; generic algorithms that include non-medical traits, such as a propensity for athleticism or 'success'; etc.

Niche segments of the fertility market might emerge to cater to different kinds of decision-making preferences much as dating sites^[135](#fn135){ref-type="fn"}^ and sperm banks have done to help individuals find the 'ideal' match or donor, respectively, from a potentially vast pool of candidates. Some dating services, for example, allow members to browse the profiles of all members with 'optional tests, quizzes, or guides' to help members find their love interests. The key, however, is that individuals have the freedom to 'choose the criteria for and expansiveness of their search'.^[136](#fn136){ref-type="fn"}^ Similarly, many sperm banks allow you to peruse their websites broadly, although many offer the option to narrow the pool of donors based on basic attributes, such as hair and eye color, race, nationality, religion, education, height, weight, etc.^[137](#fn137){ref-type="fn"}^ These general searches somewhat resemble parents wading through the genomic profiles created through EPGD and involve the greatest amount of time and energy on the part of the decision maker.

Certain dating sites and sperm banks, however, ease the selection process with something akin to the individualized algorithms I imagine for EPGD.^[138](#fn138){ref-type="fn"}^ Some matchmaking sites, for example, use complex algorithms based on the member\'s 'in-depth personality profile' to find matches.^[139](#fn139){ref-type="fn"}^ As OkCupid advertises, they use 'math in the name of love', working on 'algorithms, formulas, heuristics ... to help people connect faster'.^[140](#fn140){ref-type="fn"}^ eHarmony.com proclaims their matchmaking process 'cuts out the hours wasted ... on other dating sites by showing only the matches that demonstrate compatibility with your profile.'^[141](#fn141){ref-type="fn"}^ Some sites use algorithms based not only on responses to detailed questionnaires, but also on how an individual weights the questions.^[142](#fn142){ref-type="fn"}^

Similarly, some sperm banks offer refined search mechanisms. Fairfax Cryobank, for example, offers an advanced search that allows for greater specificity than its basic search with respect to ethnicity (fined tuned by country of origin), shades of skin tone (medium light, medium dark, light, dark, or medium), hair type (straight, curly, wavy), etc. It also offers a lifestyle search that selects donors based on astrology sign, favorite subject, religion, favorite pet, personal goals, and talents.^[143](#fn143){ref-type="fn"}^ In addition, searches can be made based on physical resemblance to 'yourself, your partner or someone famous'^[144](#fn144){ref-type="fn"}^ just by uploading a photo of the person to match. Using 'sophisticated mathematical formulas', Fairfax FaceMatch^TM^ will compare the uploaded photo 'to every adult donor photo and provide results starting with the donor who most resembles the photo'.^[145](#fn145){ref-type="fn"}^

GenePeeks launched an even more sophisticated sperm bank screening service in 2014, which resembles an EPGD algorithm in that it screens for donors least likely to result in the birth of a child with a recessive genetic disease. Working with two sperm banks, the company used a patented algorithm that 'creates thousands of hypothetical offspring' based on the genotypes of the mothers and potential donors. By scanning 'the resulting "digital children," the program can "flag pairings with an increased risk of inheriting genetic disorders.'^[146](#fn146){ref-type="fn"}^ The analysis 'generates a personalized catalogue of risk-reduced donors for each prospective mother, filtering out donor matches with a high probability of passing on' the more than 500 inherited recessive diseases the company targets.^[147](#fn147){ref-type="fn"}^ Noting, in 2014, that the analysis focused only on 'simple Mendelian disorders, with a one-to-one relation between genes and phenotype', the company was nevertheless optimistic about its potential to 'consider polygenic traits in the future'.^[148](#fn148){ref-type="fn"}^

Finally, another company, DonorMatchMe, offers both expanded choice---by aggregating 'available donor information from donor banks coast to coast so you do not have to'---and personalized choice---by providing 'all available filtering options ... in addition to facial recognition technology that makes it more likely your child will look like you'.^[149](#fn149){ref-type="fn"}^ The marketing utilizes precisely the kinds of strategies I imagine providers would use for their EPGD decision-making algorithms. It first offers the possibility of expansive choice: as the website queries, 'If you want a TRUE match, why limit your search to just part of the crowd?'^[150](#fn150){ref-type="fn"}^ EPGD websites might similarly ask, 'If you want your IDEAL child, why limit your choices to nature?' Second, DonorMatchMe\'s website highlights the significance of the decision motivating the search: 'Choosing to have a child is one of the most important decisions anyone makes in their life.'^[151](#fn151){ref-type="fn"}^ One imagines exactly the same language to promote EPGD. Finally, DonorMatchMe\'s website urges future parents to use its 'algorithms ... to find your *perfect* Match', so as not 'to make searching for your *perfect* sperm or egg a frustrating chore'.^[152](#fn152){ref-type="fn"}^ Such language promises perfection through the objective, scientific method of an algorithm. Undoubtedly, EPGD clinics would promote their algorithms with similar rhetoric.

In short, one can easily envision fertility clinics offering different selection methods for EPGD along the lines of these different types of dating or sperm bank websites. Instead of eHarmony, imagine EmbryoHarmony,^[153](#fn153){ref-type="fn"}^ and instead of DonorMatchMe, imagine BabyMatch. If EPGD becomes an accepted form of ART, rather than leave parents to wade unassisted through the thicket of so much information, clinics would likely offer a range of algorithms to ease decision making. One can visualize the advertisements touting their potential to optimize the ability to find the 'ideal' parent--child match or to have children with a greater chance of health, 'success,' or well-being.

One might expect some backlash to such advertising given the reactions to 23andMe\'s patent for its Family Traits Inheritance Calculator, which was designed to predict 'six variable benign traits, including "eye color" and "muscle performance," based on how parental DNA would likely combine'.^[154](#fn154){ref-type="fn"}^ When it filed for the patent in 2008, the company considered using enhanced gamete donor selection. Ultimately, however, it decided against doing so in response to concerns that this technology amounted to 'shopping for designer donors in an effort to produce designer babies'.^[155](#fn155){ref-type="fn"}^ Whether such reactions would arise with respect to similar marketing for EPGD is uncertain. The reactions to 23andMe\'s patent reflect today\'s perspectives in light of current technologies. If as I predict, EPGD will develop gradually in response to technological advances and an ever-expanding scope of prenatal testing, it is not implausible (even if troubling) to believe society will gradually become more tolerant of the fine-tuned selection of EPGD and its associated algorithms.

### B.. The Problems with Algorithms {#sec2-5-2}

While algorithms could potentially be very helpful in assisting parents with the potentially paralysing choices of embryo selection through EPGD, they raise general and specific issues, depending on who develops them. Section V.B.1 describes the general impact of algorithms on reproductive decision making, while Sections V.B.2. and V.B.3 discuss the issues that might arise, respectively, if professionals and commercial entities developed algorithms for EPGD.

#### 1.. The Impact of Algorithms on Reproductive Decision Making {#sec2-5-2-1}

I begin by examining the general impact of using algorithms in this context.^[156](#fn156){ref-type="fn"}^ Some might find it unsettling to use algorithms to select embryos because they rely on concrete expressions of preferences unlike selecting embryos in a more amorphous way. This concern, however, argues against EPGD itself or even ordinary PGD and prenatal testing. Inherent in the concept of EPGD is the idea that some embryos have genomic profiles that are more desirable (by whatever measure) than others. As long as parents use reproductive technologies to choose among embryos (or make decisions about pregnancies), certain preferences (whether expressed in mathematical formulas or not) inevitably shape those decisions. We cannot, therefore, fault algorithms on these grounds as long as we condone PGD and prenatal testing.

Others might argue, however, that algorithms for EPGD have the potential to enhance decision making by allowing individuals to manage complex amounts of information in systematic and consistent ways.^[157](#fn157){ref-type="fn"}^ To the extent that individualized algorithms would accurately reflect individual preferences, they might seem like a more rational mechanism for decision making than the unsystematic way most of us make decisions involving complex costs and benefits. This argument presumes, however, that people have a clear understanding of and can articulate their values and preferences (generally and in this context). The more complex and elaborate the individualized algorithms, the more likely people would opt for generic algorithms, which would be problematic for several reasons.

First, we might worry that using generic algorithms would be an abdication of decision making with respect to a technology intended to enhance reproductive choice.^[158](#fn158){ref-type="fn"}^ It might also challenge some presumptions underlying informed consent and genetic counseling norms: that individuals should be fully engaged in and willing to make their own reproductive decisions.^[159](#fn159){ref-type="fn"}^ Of course, if the goal of EPGD is to expand choice, one could argue that the option to use generic algorithms is not an abdication of choice, but, instead, a decision about *how* to decide. Indeed, in a world where EPGD was widely accepted, one might argue that reproducing the 'old-fashioned' way would be the true abdication of procreative choice. Rather than let 'nature' randomly dictate the outcome, using a generic algorithm with EPGD would be a choice to let some notion of 'better' or 'best' determine who will ultimately be born.

Moreover, people often turn to others---physicians, loved ones, or religious advisors---when making difficult medical or personal decisions.^[160](#fn160){ref-type="fn"}^ These decision-making approaches, however, are quite different from allowing a generic algorithm, created by an impersonal entity---whether a provider or a company---to decide which embryos to implant. Typically, we relinquish decision-making authority for important decisions to those who have special knowledge of us and our individual circumstances. Generic algorithms, however, falsely suggest a uniformity of views^[161](#fn161){ref-type="fn"}^ regarding genetic information and its relevance to reproductive decision making. By definition, they do not depend on, and therefore could easily lead to decisions inconsistent with, individual values or preferences.^[162](#fn162){ref-type="fn"}^

Another troubling feature of generic algorithms is the possibility that biases might shape reproductive outcomes.^[163](#fn163){ref-type="fn"}^ Decisions about which criteria (serious disease risks, minor diseases, and/or non-medical traits) to consider and their weight in the algorithm would reflect value judgements about the relevance and appropriateness of using such information to select embryos.^[164](#fn164){ref-type="fn"}^ What\'s worse, the embedded biases and values would be largely hidden.^[165](#fn165){ref-type="fn"}^ As a result, the algorithmic selection could potentially be misperceived as scientific, objective, and even medically optimal, rather than a mathematical expression of values and preferences. Indeed, the appeal of these algorithms might be precisely their apparent objectivity.^[166](#fn166){ref-type="fn"}^

Finally, by eliminating the randomness of 'old-fashioned' reproduction, we might see less diversity in those born via EPGD, particularly if most, or a respectable minority, relied on generic algorithms. By standardizing reproductive choices based on the variants that were especially determinative in the program, algorithms would tend to favor certain kinds of traits (medical or non-medical) and disfavor others. This would be less likely with individualized algorithms, as long as individual preferences were sufficiently variable.^[167](#fn167){ref-type="fn"}^

From one perspective, the potential reduction in diversity might not be all bad if generic algorithms resulted in fewer children born with debilitating and serious diseases (most algorithms would be heavily weighted against such conditions) and more children born with higher 'quality adjusted life years'.^[168](#fn168){ref-type="fn"}^ Such outcomes would be consistent with the values of most parents pursuing EPGD, who likely chose this method of reproduction, in part, to minimize suffering in their children. Otherwise, why go to the trouble of using EPGD; why not simply rely on 'old-fashioned' reproduction?^[169](#fn169){ref-type="fn"}^

On the other hand, the lack of variability that might occur if embryos were selected with generic algorithms would be troubling. We might worry about the long-term evolutionary implications, if they reduced genetic diversity. How much generic algorithms would reduce diversity (at least with respect to the loci that would be strong determinants of the algorithms' outcomes) would depend on how widely the public embraced EPGD and generic algorithms.

Even if generic algorithms didn't pose an evolutionary threat, the societal effects of insufficient diversity are troubling. If generic algorithms are used widely, they would lead to routinization of reproductive choices on a profoundly different scale than we currently see with reproductive testing^[170](#fn170){ref-type="fn"}^ or might see with EPGD alone. The effects of the algorithms would dwarf cultural pressures that influence routinization. Rather than push people toward particular choices, as cultural pressures do today (and might do with EPGD), the algorithms would literally 'choose' embryos for implantation in a systematic and comprehensive way. Such choices could stigmatize the groups routinely screened against,^[171](#fn171){ref-type="fn"}^ ultimately leading to and/or reinforcing discrimination against those groups.^[172](#fn172){ref-type="fn"}^ What\'s worse, these biases against or in favor of certain groups would be hidden in the mathematical equations, making the choices seem 'objective'.

Algorithms heighten concerns about EPGD in other ways. As noted earlier, EPGD's highly refined selection raises the possibility of heightened expectations about one\'s future child, which might be dashed if the child did not fulfill those parental expectations. Similarly the 'choice overload effect' of EPGD could potentially lead to dissatisfaction with the future child.^[173](#fn173){ref-type="fn"}^ Algorithms, however, might make such dissatisfaction *especially* likely because, in being designed to help parents make the 'best' choices, they would further heighten parental expectations. Marketing would only exacerbate that effect. But individualized algorithms would be even worse because they would be promoted as finely tuning selection based on the particular preferences of the parents, leading to even stronger expectations of having their 'ideal' child.

To be sure, there have always been worries that prenatal selection encourages future parents to fixate on the future child in terms of the presence or absence of a particular trait (which to date has mostly been diseases). But if selection addresses a much broader spectrum of the future child\'s traits, and if algorithms promise to increase the odds of successfully selecting for children with those traits, then parents\' fixation on whether the child develops the chosen or rejected traits, and the possibility of their disappointment if the child doesn\'t measure up to expectations, would increase exponentially.

Finally, the use of algorithms for EPGD decision making could further exacerbate the potential inequities discussed in Section IV.B.3. If insurers covered basic EPGD, but not the algorithmic analysis, this might indirectly limit access to either EPGD or refined use of the selection method. Further, if EPGD creates choice overload and leads some to opt out of choosing altogether, people who could not afford the additional costs of the algorithms would either avoid EPGD or end up choosing in a more limited way. Either way, they would not have the opportunity to make the more finely tuned selections that algorithms would allow. To the extent that algorithms allow for the ability to select on the basis of a combination of traits that offer societal advantages, we would once again see individuals of higher socioeconomic status multiplying the opportunities for their future children in stark contrast to those with fewer economic resources.

#### 2.. Professional Group\'s Algorithms {#sec2-5-2-2}

Quite apart from general concerns about algorithms, particularly generic algorithms, specific concerns might arise based on who develops the algorithms. In many ways, medical professionals or professional societies seem best suited for the task. They play a significant role in medical decision making. They have special insight and expertise as to what information is clinically relevant and the kinds of considerations that influence reproductive decisions. Genetics professionals, in particular, would have particular knowledge about different genetic variants---including the expressivity and penetrance of medical and non-medical traits---to create meaningful categories for algorithms. Finally, health care providers have fiduciary duties to their patients.

Nevertheless, the development of generic algorithms by medical professionals might challenge their professional norms and identities in several ways. Such algorithms would deviate from the long-held perspective that the right reproductive choice for one person might not be the right choice for another. A generic algorithm by definition would imply that one size actually does fit all.

Developing generic algorithms would also depart from the neutral stance that such professionals, particularly genetic counselors, have long advocated. Even though patients would presumably have the option to reject the algorithms, assigning relative values to different genetic variants would overtly signal that the profession is not actually neutral about the reproductive choices. That the profession isn't neutral is not in and of itself a problem (or even a revelation^[174](#fn174){ref-type="fn"}^). But knowing that the profession is not neutral is altogether different from professionals expressing their biases in a program that could literally determine patients' decisions. Further, professionals might have unique biases that do not reflect those of the patient or broader population, which could distort decision making, particularly if their generic algorithms were widely adopted. It is hard to imagine precisely what those biases might be, should EPGD become a viable technology, but it is not unlikely that professionals may have strong views about the kinds of traits that parents should or should not select against, which may not always align with an individual\'s views, particularly regarding information about more minor medical risks or non-medical traits.^[175](#fn175){ref-type="fn"}^

Finally, influencing reproductive decision making in this manner would be reminiscent of the eugenics era when genetics professionals advocated for policies intended to shape reproductive decisions. Although the field of clinical genetics grew out of this movement,^[176](#fn176){ref-type="fn"}^ clinical geneticists and genetic counselors have worked hard to distance themselves from eugenics.^[177](#fn177){ref-type="fn"}^ Creating genetic algorithms would directly contravene such efforts.

Beyond concerns about professional identities and norms, we might further worry that the creation of generic algorithms by professionals would make these algorithms inordinately enticing. When faced with the overwhelming task of selecting from a multitude of embryos or providing input for individualized algorithms, people might find generic algorithms created by the very professionals to whom they turn for reproductive guidance a calming alternative in the chaos of choice.

Adding to this concern is the risk that algorithms developed by medical professionals would enhance the sense that they offered medically 'objective' methods for selecting embryos.^[178](#fn178){ref-type="fn"}^ Relying on them would not be like deferring to the expertise of professionals the way one might defer to a surgeon regarding the optimal surgical procedure. Neither is it like considering professional views when facing difficult decisions.^[179](#fn179){ref-type="fn"}^ Instead, selecting embryos based on a generic algorithm would literally be handing over the decision to the algorithm, whose formula would have been shaped by the (largely hidden) values and biases of the professionals who created it. In many ways, this would amount to professionals giving advice about non-medical matters, which exceeds the scope of their expertise. In so doing, it would blur the lines between medical advice grounded in scientific knowledge and physicians\' social or individual preferences.

There is reason to be troubled by this. Even today, reproductive decisions (such as choosing to undergo prenatal screening or testing) are often seen as medically responsible decisions, rather than personal decisions.^[180](#fn180){ref-type="fn"}^ Professionally created generic algorithms might similarly be viewed as the medically responsible way to decide which embryo to select, particularly when alternative methods could be overwhelming. That perspective might further tempt patients to forego individualized decision making in favor of generic algorithms, enhancing concerns about the societal effects of algorithms dramatically routinizing reproductive choices.^[181](#fn181){ref-type="fn"}^

#### 3.. Commercial Algorithms {#sec2-5-2-3}

Finally, if algorithms were created by companies operating outside the clinical setting, where the fiduciary obligations of the doctor--patient relationship do not apply, we might worry about market forces influencing consumer demand. The market power to routinize this kind of decision making would potentially be much greater in this context for a few reasons. First, advertising would build on the notion that 'good' parents use not only EPGD but also algorithms because this is the optimal way to select embryos with the best prospects for health and longevity (much like NIPT marketing has done).^[182](#fn182){ref-type="fn"}^ Second, because many algorithms would also incorporate information about genotypes associated with non-medical traits, such companies would promote their algorithms as offering the best method to choose an embryo with socially competitive advantages. Third, if such efforts were successful, market pressures would push toward expansive genetic analysis and potentially also toward *specific* outcomes based on whatever genetic variants the algorithms favored and disfavored. If widely used, these algorithms could narrow reproductive decisions in ways we have never seen. Moreover, because profit motives, rather than fiduciary obligations, would shape the algorithm design, the underlying biases would be much more problematic than in the clinical setting. The marketing and development of the programs would be based on what sells, not what is 'best' for patients, however that is understood by health care professionals in this context.^[183](#fn183){ref-type="fn"}^

For all of these reasons, there is reason to worry that algorithms, even if intended to address challenging decision making, will create their own sets of issues for patients, society, and even some health care providers. The remedy may truly be worse than the disease it seeks to cure.

CONCLUSION {#sec3}
==========

Having described various concerns regarding EPGD and efforts to address the related decision-making challenges, I concede that this article explores a future that is speculative, even if highly plausible. We cannot know with certainty what technological advances will be possible and what the institutional and cultural reactions will be to those that unfold. But because new technologies often emerge before we have contemplated their implications, and because efforts are already under way to advance the very technologies that would make EPGD possible, this article is a call to pause and consider what EPGD would mean for parents, society, and the potential providers of EPGD.

If EPGD were to become a viable technology, it would raise and exacerbate many of the same issues we have faced with other reproductive technologies---their impact on the experience of reproduction, their influence on societal norms and behavior, and their implications for reproductive decision making. Contemplating a world where EPGD is the norm pushes us to consider the potential harms of unlimited, unrestricted reproductive choice and to recognize that the promise of expansive options may ultimately be illusory. In this article, I hope to demonstrate that the tyranny of choice could lead to the abdication of choice by some, which may lead to efforts by professional groups, fertility clinics, and commercial labs to intervene. It concludes that some of the potential efforts to ameliorate the tyranny of choice---such as restrictions of information or decision-making algorithms---may raise their own sets of issues for individuals, professionals, and society. For all of these reasons, my hope is that a careful examination of EPGD, before it becomes a viable option, will prevent us from adopting this new technology simply because technological advances seem to propel us inevitably toward it. Instead, we should think carefully about what kind of reproductive choice we want and whether it offers all that it promises.
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